Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury

RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury

(2016) K Newton et al.   CELL DEATH AND DIFFERENTIATION

Generation of small molecules to interfere with regulated necrosis

(2016) Alexei Degterev et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis

(2016) Boris Strilic et al.   NATURE

Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells

(2016) C Safferthal et al.   ONCOGENE

HSP90 activity is required for MLKL oligomerisation and membrane translocation and the induction of necroptotic cell death

(2016) A V Jacobsen et al.   Cell Death & Disease

Modulation of Autophagy by Sorafenib: Effects on Treatment Response

(2016) Nestor Prieto-Domínguez et al.   Frontiers in Pharmacology

Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status

(2015) Martina Broecker-Preuss et al.   BMC CANCER

Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells

(2015) Sofie Steinwascher et al.   CANCER LETTERS

NF-κB-Independent Role of IKKα/IKKβ in Preventing RIPK1 Kinase-Dependent Apoptotic and Necroptotic Cell Death during TNF Signaling

(2015) Yves Dondelinger et al.   MOLECULAR CELL

Necroptosis and its role in inflammation

(2015) Manolis Pasparakis et al.   NATURE

A cytosolic heat shock protein 90 and cochaperone CDC37 complex is required for RIP3 activation during necroptosis

(2015) Dianrong Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis

(2015) A Fauster et al.   Cell Death & Disease

Structure Guided Design of Potent and Selective Ponatinib-Based Hybrid Inhibitors for RIPK1

(2015) Malek Najjar et al.   Cell Reports

Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection

(2015) Ashwini Benedict et al.   Frontiers in Microbiology

Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis

(2014) A. Ramírez-Labrada et al.   Clinical & Translational Oncology

Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia

(2014) Naveen Pemmaraju et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

RIP3 Induces Apoptosis Independent of Pronecrotic Kinase Activity

(2014) Pratyusha Mandal et al.   MOLECULAR CELL

Mixed Lineage Kinase Domain-like Protein MLKL Causes Necrotic Membrane Disruption upon Phosphorylation by RIP3

(2014) Huayi Wang et al.   MOLECULAR CELL

Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks

(2014) Stephen M Strittmatter   NATURE MEDICINE

Regulated necrosis: the expanding network of non-apoptotic cell death pathways

(2014) Tom Vanden Berghe et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death

(2014) Joanne M. Hildebrand et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Activity of Protein Kinase RIPK3 Determines Whether Cells Die by Necroptosis or Apoptosis

(2014) K. Newton et al.   SCIENCE

The B-RafV600E inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury

(2014) J-X Li et al.   Cell Death & Disease

Pro-apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivo

(2014) R Sonntag et al.   Cell Death & Disease

MLKL Compromises Plasma Membrane Integrity by Binding to Phosphatidylinositol Phosphates

(2014) Yves Dondelinger et al.   Cell Reports

RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition

(2013) Y Dondelinger et al.   CELL DEATH AND DIFFERENTIATION

Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death

(2013) Xin Chen et al.   CELL RESEARCH

Necroptosis: The Release of Damage-Associated Molecular Patterns and Its Physiological Relevance

(2013) Agnieszka Kaczmarek et al.   IMMUNITY

Determination of apoptotic and necrotic cell death in vitro and in vivo

(2013) Tom Vanden Berghe et al.   METHODS

Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis

(2013) Zhenyu Cai et al.   NATURE CELL BIOLOGY

Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury

(2013) A. Linkermann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural Basis of RIP1 Inhibition by Necrostatins

(2013) Tian Xie et al.   STRUCTURE

Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis

(2013) L Steinhart et al.   Cell Death & Disease

Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis

(2013) Philip A. Harris et al.   ACS Medicinal Chemistry Letters

Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase

(2012) Liming Sun et al.   CELL

Sorafenib for the treatment of renal cancer

(2012) Dirk Strumberg   EXPERT OPINION ON PHARMACOTHERAPY

Rip1 (Receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury

(2012) Andreas Linkermann et al.   KIDNEY INTERNATIONAL

Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis

(2012) Ying-Ying Yang et al.   LIVER TRANSPLANTATION

Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models

(2012) N Takahashi et al.   Cell Death & Disease

The Inflammatory Microenvironment in Hepatocellular Carcinoma: A Pivotal Role for Tumor-Associated Macrophages

(2012) Daria Capece et al.   Biomed Research International

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

RIP Kinase-Dependent Necrosis Drives Lethal Systemic Inflammatory Response Syndrome

(2011) Linde Duprez et al.   IMMUNITY

FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation

(2011) Patrick-Simon Welz et al.   NATURE

RIP3 mediates the embryonic lethality of caspase-8-deficient mice

(2011) William J. Kaiser et al.   NATURE

Catalytic activity of the caspase-8–FLIPL complex inhibits RIPK3-dependent necrosis

(2011) Andrew Oberst et al.   NATURE

Comparison of the Luminescent ADP-Glo Assay to a Standard Radiometric Assay for Measurement of Protein Kinase Activity

(2010) Jasbinder Sanghera et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

Molecular mechanisms of necroptosis: an ordered cellular explosion

(2010) Peter Vandenabeele et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced Inflammation

(2009) YoungSik Cho et al.   CELL

Receptor Interacting Protein Kinase-3 Determines Cellular Necrotic Response to TNF-α

(2009) Sudan He et al.   CELL

HCV-related hepatocellular carcinoma: From chronic inflammation to cancer

(2009) Giuseppe Castello et al.   CLINICAL IMMUNOLOGY

New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication

(2009) K. Himmelsbach et al.   GUT

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo

(2009) J.-Y. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice

(2009) V. Echeverria et al.   NEUROSCIENCE

RIP3, an Energy Metabolism Regulator That Switches TNF-Induced Cell Death from Apoptosis to Necrosis

(2009) D.-W. Zhang et al.   SCIENCE

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Identification of RIP1 kinase as a specific cellular target of necrostatins

(2008) Alexei Degterev et al.   Nature Chemical Biology